{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:20:45Z","timestamp":1747207245253,"version":"3.40.5"},"reference-count":196,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The advent and spread of novel coronavirus (nCoV) has posed a new public health crisis\nsince December 2019. Several cases of unexplained pneumonia occurred in Wuhan, Hubei\nProvince, China, only a month before the Chinese Spring festival. After the diagnosis of bronchoalveolar\nfluid samples of people infected, the new coronavirus was identified using nextgeneration\nsequence technology. This work aims to provide information regarding COVID-19\nthat will help the researchers to identify the vital therapeutic targets for SARS-CoV-2 and also\nwill provide insights into some significant findings of recent times highlighted by scientific communities\naround the globe. In this review, we have tried to explore multiple aspects related to\nCOVID-19, including epidemiology, etiology, COVID-19 variants, vaccine candidates, potential\ntherapeutic targets, the role of natural products, and computational studies in drug design and development,\nrepurposing, and analysis of crystal structures available for COVID-19 related protein\nstructures. Druggable targets include all viral enzymes and proteins involved in viral replication\nand regulation of host cellular machines. The medical community tracks several therapies to combat\nthe infection by investigating various antiviral and immunomodulatory mechanisms. While\nsome vaccines are approved in this worldwide health crisis, a more precise therapy or drug is formally\nrecommended to be used against SARS-CoV-2 infection. Natural products other than synthetic\ndrugs have been tested by in silico analysis against COVID-19. However, important issues\nstill need to be addressed regarding in vivo bioavailability and better efficacy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201023666220507003726","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T10:27:19Z","timestamp":1651919239000},"page":"988-1017","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Multi-dimensional Review on Severe Acute Respiratory Syndrome\nCoronavirus-2"],"prefix":"10.2174","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2300-9732","authenticated-orcid":true,"given":"Ketan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar,\nIndia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bumba","family":"Chattopadyay","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Calcutta Institute of Pharmaceutical Technology and Allied Science,\nUluberia, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapas","family":"Maity","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology Process Chemistry, National Institute of Pharmaceutical\nEducation and Research, S.A.S. Nagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayan","family":"Acharya","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, National Institute of Pharmaceutical\nEducation and Research, S.A.S. Nagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"955","DOI":"10.4269\/ajtmh.20-0849","volume":"103","author":"Morens D.M.","year":"2020","unstructured":"Morens D.M.; Breman J.G.; Calisher C.H.; Doherty P.C.; Hahn B.H.; Keusch G.T.; Kramer L.D.; LeDuc J.W.; Monath T.P.; Taubenberger J.K.; The origin of COVID-19 and why it matters. Am J Trop Med Hyg 2020,103(3),955-959","journal-title":"Am J Trop Med Hyg"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.sjbs.2020.04.033","volume":"27","author":"Al-Qahtani A.A.","year":"2020","unstructured":"Al-Qahtani A.A.; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects. Saudi J Biol Sci 2020,27(10),2531-2538","journal-title":"Saudi J Biol Sci"},{"key":"ref=3","first-page":"E64","volume":"60","author":"Martini M.","year":"2019","unstructured":"Martini M.; Gazzaniga V.; Bragazzi N.L.; Barberis I.; The Spanish Influenza Pandemic: a lesson from history 100 years after 1918. J Prev Med Hyg 2019,60(1),E64-E67","journal-title":"J Prev Med Hyg"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","volume":"87","author":"Singhal T.","year":"2020","unstructured":"Singhal T.; A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr 2020,87(4),281-286","journal-title":"Indian J Pediatr"},{"key":"ref=5","author":"Richman D.D.","year":"2020","unstructured":"Richman D.D.; Whitley R.J.; Hayden F.G.;  Clinical Virology John Wiley andamp 2020","journal-title":"Clinical Virology John Wiley andamp"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"Cui J.","year":"2019","unstructured":"Cui J.; Li F.; Shi Z.L.; Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019,17(3),181-192","journal-title":"Nat Rev Microbiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1003500","DOI":"10.1371\/journal.ppat.1003500","volume":"9","author":"Lauber C.","year":"2013","unstructured":"Lauber C.; Goeman J.J.; The Footprint of Genome Architecture in the Largest Genome Expansion in RNA Viruses. PLoS Pathog;Stern, A, Ed 2013,9(7),1003500","journal-title":"PLoS Pathog;Stern, A, Ed"},{"key":"ref=8","unstructured":"International Committee on Taxonomy of Viruses (2010) ICTV Master Species List 2009. 2010.  (Accessed on 4 Mar 2022). (XLS)"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1128\/CMR.00102-14","volume":"28","author":"Chan J.F.W.","year":"2015","unstructured":"Chan J.F.W.; Lau S.K.P.; To K.K.W.; Cheng V.C.C.; Woo P.C.Y.; Yuen K.Y.; Middle East respiratory syndrome coronavirus: Another zoonotic betacorona virus causing SARS-like disease. Clin Microbiol Rev 2015,28(2),465-522","journal-title":"Clin Microbiol Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","volume":"367","author":"Zaki A.M.","year":"2012","unstructured":"Zaki A.M.; van Boheemen S.; Bestebroer T.M.; Osterhaus A.D.M.E.; Fouchier R.A.M.; Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012,367(19),1814-1820","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"581521","DOI":"10.3389\/fmed.2020.581521","volume":"7","author":"Mann R.","year":"2020","unstructured":"Mann R.; Perisetti A.; Gajendran M.; Gandhi Z.; Umapathy C.; Goyal H.; Clinical characteristics, diagnosis, and treatment of major coronavirus outbreaks. Front Med (Lausanne) 2020,7(1),581521","journal-title":"Front Med (Lausanne)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","year":"2020","unstructured":"The species severe acute respiratory syndrome-related coronavirus: Classifying 2019- nCoV and naming it SARS-CoV-2. Nat Microbiol 2020,5(4),536-544","journal-title":"Nat Microbiol"},{"key":"ref=13","unstructured":"COVID-19 Weekly Epidemiological Update by World Health Organization. 2021. Available from: (Accessed on 4 Mar 2022)."},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"608810","DOI":"10.3389\/fpubh.2021.608810","volume":"9","author":"Joshi A.","year":"2021","unstructured":"Joshi A.; Mewani A.H.; Arora S.; Grover A.; India\u2019s COVID-19 Burdens, 2020. Front Public Health 2021,9,608810","journal-title":"Front Public Health"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.3389\/fimmu.2020.01991","volume":"11","author":"Callender L.A.","year":"2020","unstructured":"Callender L.A.; Curran M.; Bates S.M.; Mairesse M.; Weigandt J.; Betts C.J.; The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Front Immunol 2020,11,1991","journal-title":"Front Immunol"},{"key":"ref=16","first-page":"13","volume":"4","author":"Rather Ra.","year":"2021","unstructured":"Rather Ra.; Islam T.; Rehman Iul, Pandey D. Development of vaccine against coronavirus disease 2019 (Covid-19) In India. Asian J Adv Med Sci 2021,4,13-21","journal-title":"Asian J Adv Med Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"118275","DOI":"10.1016\/j.lfs.2020.118275","volume":"259","author":"Parvathaneni V.","year":"2020","unstructured":"Parvathaneni V.; Gupta V.; Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. Life Sci 2020,259,118275","journal-title":"Life Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"23379","DOI":"10.1039\/D0RA03774E","volume":"10","author":"da Silva Antonio A.","year":"2020","unstructured":"da Silva Antonio A.; Wiedemann L.S.M.; Veiga-Junior V.F.; Natural products\u2019 role against COVID-19. RSC Advances 2020,10,23379-23393","journal-title":"RSC Advances"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.3390\/molecules25173980","volume":"25","author":"Muchtaridi M.","year":"2020","unstructured":"Muchtaridi M.; Fauzi M.; Khairul Ikram N.K.; Mohd Gazzali A.; Wahab H.A.; Natural flavonoids as potential angiotensin-converting enzyme 2 inhibitors for anti-SARS-CoV-2. Molecules 2020,25(17),3980","journal-title":"Molecules"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"Lan J.","year":"2020","unstructured":"Lan J.; Ge J.; Yu J.; Shan S.; Zhou H.; Fan S.; Zhang Q.; Shi X.; Wang Q.; Zhang L.; Wang X.; Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020,581(7807),215-220","journal-title":"Nature"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jpha.2020.04.008","volume":"10","author":"Mirza M.U.","year":"2020","unstructured":"Mirza M.U.; Froeyen M.; Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J Pharm Anal 2020,10(4),320-328","journal-title":"J Pharm Anal"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1080\/07391102.2020.1779818","volume":"39","author":"Ghosh R.","year":"2021","unstructured":"Ghosh R.; Chakraborty A.; Biswas A.; Chowdhuri S.; Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study. J Biomol Struct Dyn 2021,39(12),4362-4374","journal-title":"J Biomol Struct Dyn"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/med.21728","volume":"41","author":"Wang X.","year":"2021","unstructured":"Wang X.; Guan Y.; COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. Med Res Rev 2021,41(1),5-28","journal-title":"Med Res Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"104490","DOI":"10.1016\/j.bioorg.2020.104490","volume":"106","author":"Mohamed K.","year":"2021","unstructured":"Mohamed K.; Yazdanpanah N.; Saghazadeh A.; Rezaei N.; Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review. Bioorg Chem 2021,106,104490","journal-title":"Bioorg Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.addr.2021.02.004","volume":"172","author":"Hwang W.","year":"2021","unstructured":"Hwang W.; Lei W.; Katritsis N.M.; MacMahon M.; Chapman K.; Han N.; Current and prospective computational approaches and challenges for developing COVID-19 vaccines. Adv Drug Deliv Rev 2021,172,249-274","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1021\/acs.jproteome.0c00553","volume":"19","author":"Tilocca B.","year":"2020","unstructured":"Tilocca B.; Britti D.; Urbani A.; Roncada P.; Computational immune proteomics approach to target COVID-19. J Proteome Res 2020,19(11),4233-4241","journal-title":"J Proteome Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.2174\/1568026620666200710105507","volume":"20","author":"Shanmugam A.","year":"2020","unstructured":"Shanmugam A.; Muralidharan N.; Velmurugan D.; Gromiha M.M.; Therapeutic targets and computational approaches on drug development for COVID-19. Curr Top Med Chem 2020,20(24),2210-2220","journal-title":"Curr Top Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cegh.2020.07.006","volume":"9","author":"Frediansyah A.","year":"2021","unstructured":"Frediansyah A.; Tiwari R.; Sharun K.; Dhama K.; Harapan H.; Antivirals for COVID-19: A critical review. Clin Epidemiol Glob Health 2021,9,90-98","journal-title":"Clin Epidemiol Glob Health"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43588-020-00007-6","volume":"1","author":"Galindez G.","year":"2021","unstructured":"Galindez G.; Matschinske J.; Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nat Comput Sci 2021,1(1),33-41","journal-title":"Nat Comput Sci"},{"key":"ref=30","first-page":"3387","volume":"39","author":"Al-Khafaji K.","year":"2021","unstructured":"Al-Khafaji K.; Al-Duhaidahawi D.; Taskin Tok T.; Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2. J Biomol Struct Dyn 2021,39(9),3387-3395","journal-title":"J Biomol Struct Dyn"},{"key":"ref=31","first-page":"51","volume":"22","author":"Abd E.W.","year":"2020","unstructured":"Abd E.W.; Eassa S.M.; Metwally M.; Al-Hraishawi H.; Omar S.R.; SARS-CoV-2 Transmission channels: A review of the literature. MEDICC Rev 2020,22(4),51-69","journal-title":"MEDICC Rev"},{"key":"ref=32","first-page":"1449","volume":"2","author":"Singh B.","year":"2020","unstructured":"Singh B.; Kumar V.; Tripathi S.; A review of Covid-19 based on current evidences. Int Res J Mod Eng Technol Sci 2020,2(8),1449-1459","journal-title":"Int Res J Mod Eng Technol Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e00473","DOI":"10.1128\/mBio.00473-12","volume":"3","author":"van Boheemen S.","year":"2012","unstructured":"van Boheemen S.; de Graaf M.; Lauber C.; Bestebroer T.M.; Raj V.S.; Zaki A.M.; Osterhaus A.D.; Haagmans B.L.; Gorbalenya A.E.; Snijder E.J.; Fouchier R.A.; Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012,3(6),e00473-e12","journal-title":"MBio"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature12005","volume":"495","author":"Raj V.S.","year":"2013","unstructured":"Raj V.S.; Mou H.; Smits S.L.; Dekkers D.H.; M&#xFC;ller M.A.; Dijkman R.; Muth D.; Demmers J.A.; Zaki A.; Fouchier R.A.; Thiel V.; Drosten C.; Rottier P.J.; Osterhaus A.D.; Bosch B.J.; Haagmans B.L.; Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013,495(7440),251-254","journal-title":"Nature"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e00127","DOI":"10.1128\/JVI.00127-20","volume":"94","author":"Wan Y.","year":"2020","unstructured":"Wan Y.; Shang J.; Graham R.; Baric R.S.; Li F.; Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020,94(7),e00127-e20","journal-title":"J Virol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"de Wit E.","year":"2016","unstructured":"de Wit E.; van Doremalen N.; Falzarano D.; Munster V.J.; SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016,14(8),523-534","journal-title":"Nat Rev Microbiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1152\/physiolgenomics.00087.2020","volume":"53","author":"Ashraf U.M.","year":"2021","unstructured":"Ashraf U.M.; Abokor A.A.; Edwards J.M.; Waigi E.W.; Royfman R.S.; Hasan S.A.; Smedlund K.B.; Hardy A.M.G.; Chakravarti R.; Koch L.G.; SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol Genomics 2021,53(2),51-60","journal-title":"Physiol Genomics"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/brainsci10070465","volume":"10","year":"2020","unstructured":"Dro &#x17C;d&#x17C; al, S.; Rosik, J.; Lechowicz, K.; Machaj, F.; Szostak, B.; Majewski, P.; Rotter, I.; Kotfis, K. COVID-19: Pain management in patients with SARS-CoV-2 infection\u2014molecular mechanisms, challenges, and perspectives. Brain Sci 2020,10(7),465","journal-title":"Brain Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Kleine-Weber H.; Schroeder S.; Kr&#xFC;ger N.; Herrler T.; Erichsen S.; Schiergens T.S.; Herrler G.; Wu N.H.; Nitsche A.; M&#xFC;ller M.A.; Drosten C.; P&#xF6;hlmann S.; SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280.e8","journal-title":"Cell"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3389\/fphar.2020.01169","volume":"11","author":"Hussman J.P.","year":"2020","unstructured":"Hussman J.P.; Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention. Front Pharmacol 2020,11,1169","journal-title":"Front Pharmacol"},{"key":"ref=41","first-page":"639","volume":"52","author":"Touyz R.M.","year":"2000","unstructured":"Touyz R.M.; Schiffrin E.L.; Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000,52(4),639-672","journal-title":"Pharmacol Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","volume":"50","author":"Murakami M.","year":"2019","unstructured":"Murakami M.; Kamimura D.; Hirano T.; Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity 2019,50(4),812-831","journal-title":"Immunity"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"Moore J.B.","year":"2020","unstructured":"Moore J.B.; June C.H.; Cytokine release syndrome in severe COVID-19. Science 2020,368(6490),473-474","journal-title":"Science"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"102763","DOI":"10.1016\/j.ebiom.2020.102763","volume":"55","author":"Liu L.","year":"2020","unstructured":"Liu L.; J; Li, S Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMed 2020,55,102763","journal-title":"EBioMed"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.chom.2020.03.021","volume":"27","author":"Ong E.Z.","year":"2020","unstructured":"Ong E.Z.; Chan Y.F.Z.; Leong W.Y.; Lee N.M.Y.; Kalimuddin S.; Haja Mohideen S.M.; Chan K.S.; Tan A.T.; Bertoletti A.; Ooi E.E.; Low J.G.H.; A dynamic immune response shapes COVID-19 progression. Cell Host Microbe 2020,27(6),879-882.e2","journal-title":"Cell Host Microbe"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1038\/s41467-021-21918-6","volume":"12","author":"Kutter J.S.","year":"2021","unstructured":"Kutter J.S.; de Meulder D.; Bestebroer T.M.; Lexmond P.; Mulders A.; Richard M.; Fouchier R.A.M.; Herfst S.; SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more than one meter distance. Nat Commun 2021,12(1),1653","journal-title":"Nat Commun"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"594495","DOI":"10.3389\/fmed.2020.594495","volume":"7","author":"Salamanna F.","year":"2020","unstructured":"Salamanna F.; Maglio M.; Landini M.P.; Fini M.; Body localization of ACE-2: On the trail of the keyhole of SARS-CoV-2. Front Med (Lausanne) 2020,7,594495","journal-title":"Front Med (Lausanne)"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"200347","DOI":"10.1098\/rsob.200347","volume":"11","author":"Roychoudhury S.","year":"2021","unstructured":"Roychoudhury S.; Das A.; Jha N.K.; Kesari K.K.; Roychoudhury S.; Jha S.K.; Kosgi R.; Choudhury A.P.; Lukac N.; Madhu N.R.; Kumar D.; Slama P.; Viral pathogenesis of SARS-CoV-2 infection and male reproductive health. Open Biol 2021,11(1),200347","journal-title":"Open Biol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/brainsci10060345","volume":"10","author":"Boziki M.K.","year":"2020","unstructured":"Boziki M.K.; Mentis A.A.; Shumilina M.; Makshakov G.; Evdoshenko E.; Grigoriadis N.; COVID-19 immunopathology and the central nervous system: Implication for multiple sclerosis and other autoimmune diseases with associated demyelination. Brain Sci 2020,10(6),345","journal-title":"Brain Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.bbi.2020.05.025","volume":"87","author":"Su S.","year":"2020","unstructured":"Su S.; Cui H.; Wang T.; Shen X.; Ma C.; Pain: A potential new label of COVID-19. Brain Behav Immun 2020,87,159-160","journal-title":"Brain Behav Immun"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.pain.2010.07.018","volume":"151","author":"Manjavachi M.N.","year":"2010","unstructured":"Manjavachi M.N.; Motta E.M.; Marotta D.M.; Leite D.F.P.; Calixto J.B.; Mechanisms involved in IL-6-induced muscular mechanical hyperalgesia in mice. Pain 2010,151(2),345-355","journal-title":"Pain"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1080\/14737159.2020.1757437","volume":"20","author":"Tahamtan A.","year":"2020","unstructured":"Tahamtan A.; Ardebili A.; Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn 2020,20(5),453-454","journal-title":"Expert Rev Mol Diagn"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"10196","DOI":"10.1021\/acs.analchem.0c02060","volume":"92","author":"Feng W.","year":"2020","unstructured":"Feng W.; Newbigging A.M.; Le C.; Pang B.; Peng H.; Cao Y.; Wu J.; Abbas G.; Song J.; Wang D.B.; Cui M.; Tao J.; Tyrrell D.L.; Zhang X.E.; Zhang H.; Le X.C.; Molecular diagnosis of COVID-19: challenges and research needs. Anal Chem 2020,92(15),10196-10209","journal-title":"Anal Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41423-020-0407-x","volume":"17","author":"Yang P.","year":"2020","unstructured":"Yang P.; Wang X.; COVID-19: A new challenge for human beings. Cell Mol Immunol 2020,17(5),555-557","journal-title":"Cell Mol Immunol"},{"key":"ref=55","first-page":"361","volume":"5","author":"Pillaiyar T.","year":"2015","unstructured":"Pillaiyar T.; Manickam M.; Jung S.H.; Middle East respiratory syndrome-coronavirus (MERS-CoV): An updated overview and pharmacotherapeutics. Med Chem 2015,5(8),361-372","journal-title":"Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","volume":"17","author":"Xia S.","year":"2020","unstructured":"Xia S.; Zhu Y.; Liu M.; Lan Q.; Xu W.; Wu Y.; Ying T.; Liu S.; Shi Z.; Jiang S.; Lu L.; Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol 2020,17(7),765-767","journal-title":"Cell Mol Immunol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.1128\/JVI.03372-12","volume":"87","author":"Bertram S.","year":"2013","unstructured":"Bertram S.; Dijkman R.; Habjan M.; Heurich A.; Gierer S.; Glowacka I.; Welsch K.; Winkler M.; Schneider H.; Hofmann-Winkler H.; Thiel V.; P&#xF6;hlmann S.; TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol 2013,87(11),6150-6160","journal-title":"J Virol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.bbrc.2007.05.092","volume":"359","author":"Du L.","year":"2007","unstructured":"Du L.; Kao R.Y.; Zhou Y.; He Y.; Zhao G.; Wong C.; Jiang S.; Yuen K.Y.; Jin D.Y.; Zheng B.J.; Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun 2007,359(1),174-179","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"Zhang H.","year":"2020","unstructured":"Zhang H.; Penninger J.M.; Li Y.; Zhong N.; Slutsky A.S.; Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020,46(4),586-590","journal-title":"Intensive Care Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e02707","DOI":"10.1128\/mBio.02707-20","volume":"11","author":"Long S.W.","year":"2020","unstructured":"Long S.W.; Olsen R.J.; Christensen P.A.; Bernard D.W.; Davis J.J.; Shukla M.; Nguyen M.; Saavedra M.O.; Yerramilli P.; Pruitt L.; Subedi S.; Kuo H.C.; Hendrickson H.; Eskandari G.; Nguyen H.A.T.; Long J.H.; Kumaraswami M.; Goike J.; Boutz D.; Gollihar J.; McLellan J.S.; Chou C.W.; Javanmardi K.; Finkelstein I.J.; Musser J.M.; Molecular architecture of early dissemination and massive second wave of the SARS-CoV-2 virus in a major metropolitan area. MBio 2020,11(6),e02707-e02720","journal-title":"MBio"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"Vogel A.B.","year":"2021","unstructured":"Vogel A.B.; Kanevsky I.; Che Y.; Swanson K.A.; Muik A.; Vormehr M.; Kranz L.M.; Walzer K.C.; Hein S.; G&#xFC;ler A.; Loschko J.; Maddur M.S.; Ota-Setlik A.; Tompkins K.; Cole J.; Lui B.G.; Ziegenhals T.; Plaschke A.; Eisel D.; Dany S.C.; Fesser S.; Erbar S.; Bates F.; Schneider D.; Jesionek B.; S&#xE4;nger B.; Wallisch A.K.; Feuchter Y.; Junginger H.; Krumm S.A.; Heinen A.P.; Adams-Quack P.; Schlereth J.; Schille S.; Kr&#xF6;ner C.; de la Caridad G&#xFC;imil Garcia R.; Hiller T.; Fischer L.; Sellers R.S.; Choudhary S.; Gonzalez O.; Vascotto F.; Gutman M.R.; Fontenot J.A.; Hall-Ursone S.; Brasky K.; Griffor M.C.; Han S.; Su A.A.H.; Lees J.A.; Nedoma N.L.; Mashalidis E.H.; Sahasrabudhe P.V.; Tan C.Y.; Pavliakova D.; Singh G.; Fontes-Garfias C.; Pride M.; Scully I.L.; Ciolino T.; Obregon J.; Gazi M.; Carrion R.; Alfson K.J.; Kalina W.V.; Kaushal D.; Shi P.Y.; Klamp T.; Rosenbaum C.; Kuhn A.N.; T&#xFC;reci &#xD6;.; Dormitzer P.R.; Jansen K.U.; Sahin U.; BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 2021,592(7853),283-289","journal-title":"Nature"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.virol.2012.07.005","volume":"432","author":"Verdi&#xE1;-B&#xE1;guena C.","year":"2012","unstructured":"Verdi&#xE1;-B&#xE1;guena C.; Nieto-Torres J.L.; Alcaraz A.; DeDiego M.L.; Torres J.; Aguilella V.M.; Enjuanes L.; Coronavirus E protein forms ion channels with functionally and structurally-involved membrane lipids. Virology 2012,432(2),485-494","journal-title":"Virology"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.bbamem.2013.05.008","volume":"1828","author":"Verdi&#xE1;-B&#xE1;guena C.","year":"2013","unstructured":"Verdi&#xE1;-B&#xE1;guena C.; Nieto-Torres J.L.; Alcaraz A.; Dediego M.L.; Enjuanes L.; Aguilella V.M.; Analysis of SARS-CoV E protein ion channel activity by tuning the protein and lipid charge. Biochim Biophys Acta 2013,1828(9),2026-2031","journal-title":"Biochim Biophys Acta"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"104792","DOI":"10.1016\/j.antiviral.2020.104792","volume":"178","author":"Tang T.","year":"2020","unstructured":"Tang T.; Bidon M.; Jaimes J.A.; Whittaker G.R.; Daniel S.; Coronavirus membrane fusion mechanism offers a potential target for antiviral development. Antiviral Res 2020,178,104792","journal-title":"Antiviral Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1099\/vir.0.80111-0","volume":"85","author":"Pang H.","year":"2004","unstructured":"Pang H.; Liu Y.; Han X.; Xu Y.; Jiang F.; Wu D.; Kong X.; Bartlam M.; Rao Z.; Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol 2004,85(Pt 10),3109-3113","journal-title":"J Gen Virol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"663688","DOI":"10.3389\/fcimb.2021.663688","volume":"11","author":"Mishra T.","year":"2021","unstructured":"Mishra T.; Sreepadmanabh M.; Ramdas P.; Sahu A.K.; Kumar A.; Chande A.; SARS CoV-2 nucleoprotein enhances the infectivity of lentiviral spike particles. Front Cell Infect Microbiol 2021,11,663688","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.tim.2020.12.007","volume":"29","author":"Suryawanshi R.K.","year":"2021","unstructured":"Suryawanshi R.K.; Koganti R.; Agelidis A.; Patil C.D.; Shukla D.; Dysregulation of cell signaling by SARS-CoV-2. Trends Microbiol 2021,29(3),224-237","journal-title":"Trends Microbiol"},{"key":"ref=68","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12085083.v1","author":"Mendoza-Martinez C.","year":"2020","unstructured":"Mendoza-Martinez C.; Rodriguez-Lezama A.; Identification of potential inhibitors of SARS-CoV-2 Main protease via a rapid in-silico drug repurposing approach. ChemRxiv 2020","journal-title":"ChemRxiv"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"Zhang L.","year":"2020","unstructured":"Zhang L.; Lin D.; Sun X.; Curth U.; Drosten C.; Sauerhering L.; Becker S.; Rox K.; Hilgenfeld R.; Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved-&#x3B1;-ketoamide inhibitors. Science 2020,368(6489),409-412","journal-title":"Science"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.abc1560","volume":"368","author":"Yin W.","year":"2020","unstructured":"Yin W.; Mao C.; Luan X.; Shen D.D.; Shen Q.; Su H.; Wang X.; Zhou F.; Zhao W.; Gao M.; Chang S.; Xie Y.C.; Tian G.; Jiang H.W.; Tao S.C.; Shen J.; Jiang Y.; Jiang H.; Xu Y.; Zhang S.; Zhang Y.; Xu H.E.; Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020,368(6498),1499-1504","journal-title":"Science"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.virusres.2007.02.017","volume":"133","author":"Graham R.L.","year":"2008","unstructured":"Graham R.L.; Sparks J.S.; Eckerle L.D.; Sims A.C.; Denison M.R.; SARS coronavirus replicase proteins in pathogenesis. Virus Res 2008,133(1),88-100","journal-title":"Virus Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","volume":"59","author":"Pillaiyar T.","year":"2016","unstructured":"Pillaiyar T.; Manickam M.; Namasivayam V.; Hayashi Y.; Jung S.H.; An overview of severe acute respiratory syndrome\u2013coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy. J Med Chem 2016,59(14),6595-6628","journal-title":"J Med Chem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1073\/pnas.0505577102","volume":"102","author":"Simmons G.","year":"2005","unstructured":"Simmons G.; Gosalia D.N.; Rennekamp A.J.; Reeves J.D.; Diamond S.L.; Bates P.; Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 2005,102(33),11876-11881","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1128\/JVI.02232-10","volume":"85","author":"Glowacka I.","year":"2011","unstructured":"Glowacka I.; Bertram S.; M&#xFC;ller M.A.; Allen P.; Soilleux E.; Pfefferle S.; Steffen I.; Tsegaye T.S.; He Y.; Gnirss K.; Niemeyer D.; Schneider H.; Drosten C.; P&#xF6;hlmann S.; Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol 2011,85(9),4122-4134","journal-title":"J Virol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"e01815","DOI":"10.1128\/JVI.01815-18","volume":"93","author":"Iwata-Yoshikawa N.","year":"2019","unstructured":"Iwata-Yoshikawa N.; Okamura T.; Shimizu Y.; Hasegawa H.; Takeda M.; Nagata N.; TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J Virol 2019,93(6),e01815-e01818","journal-title":"J Virol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"fdd-2020","DOI":"10.4155\/fdd-2020-0010","volume":"2","author":"Senanayake S.L.","year":"2020","unstructured":"Senanayake S.L.; Drug repurposing strategies for COVID-19. Future Drug Discov 2020,2(2),fdd-2020-fdd-0010","journal-title":"Future Drug Discov"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41587-020-0528-x","volume":"38","author":"Dolgin E.","year":"2020","unstructured":"Dolgin E.; Biggest COVID-19 trial tests repurposed drugs first. Nat Biotechnol 2020,38(5),510-510","journal-title":"Nat Biotechnol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"Horby P.","year":"2021","unstructured":"Horby P.; Lim W.S.; Emberson J.R.; Mafham M.; Bell J.L.; Linsell L.; Staplin N.; Brightling C.; Ustianowski A.; Elmahi E.; Prudon B.; Green C.; Felton T.; Chadwick D.; Rege K.; Fegan C.; Chappell L.C.; Faust S.N.; Jaki T.; Jeffery K.; Montgomery A.; Rowan K.; Juszczak E.; Baillie J.K.; Haynes R.; Landray M.J.; Dexamethasone in hospitalized patients with Covid-19. N Engl J Med RECOVERY Collaborative Group2021,384(8),693-704","journal-title":"N Engl J Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(20)31863-8","volume":"396","author":"Oldenburg C.E.","year":"2020","unstructured":"Oldenburg C.E.; Doan T.; Azithromycin for severe COVID-19. Lancet 2020,396(10256),936-937","journal-title":"Lancet"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s11427-020-1732-2","volume":"63","author":"Yu B.","year":"2020","unstructured":"Yu B.; Li C.; Chen P.; Zhou N.; Wang L.; Li J.; Jiang H.; Wang D.W.; Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci 2020,63(10),1515-1521","journal-title":"Sci China Life Sci"},{"key":"ref=81","first-page":"399","volume":"9","author":"Chan K.S.","year":"2003","unstructured":"Chan K.S.; Lai S.T.; Chu C.M.; Tsui E.; Tam C.Y.; Wong M.M.; Tse M.W.; Que T.L.; Peiris J.S.; Sung J.; Wong V.C.; Yuen K.Y.; Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: A multicentre retrospective matched cohort study. Hong Kong Med J 2003,9(6),399-406","journal-title":"Hong Kong Med J"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"Agostini M.L.","year":"2018","unstructured":"Agostini M.L.; Andres E.L.; Sims A.C.; Graham R.L.; Sheahan T.P.; Lu X.; Smith E.C.; Case J.B.; Feng J.Y.; Jordan R.; Ray A.S.; Cihlar T.; Siegel D.; Mackman R.L.; Clarke M.O.; Baric R.S.; Denison M.R.; Coronaviruses susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading Exoribonuclease. MBio 2018,9(2),e00221-e18","journal-title":"MBio"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Zhang D.; Du G.; Du R.; Zhao J.; Jin Y.; Fu S.; Gao L.; Cheng Z.; Lu Q.; Hu Y.; Luo G.; Wang K.; Lu Y.; Li H.; Wang S.; Ruan S.; Yang C.; Mei C.; Wang Y.; Ding D.; Wu F.; Tang X.; Ye X.; Ye Y.; Liu B.; Yang J.; Yin W.; Wang A.; Fan G.; Zhou F.; Liu Z.; Gu X.; Xu J.; Shang L.; Zhang Y.; Cao L.; Guo T.; Wan Y.; Qin H.; Jiang Y.; Jaki T.; Hayden F.G.; Horby P.W.; Cao B.; Wang C.; Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020,395(10236),1569-1578","journal-title":"Lancet"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.csbj.2020.03.025","volume":"18","author":"Beck B.R.","year":"2020","unstructured":"Beck B.R.; Shin B.; Choi Y.; Park S.; Kang K.; Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J 2020,18,784-790","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","volume":"63","author":"Gil C.","year":"2020","unstructured":"Gil C.; Ginex T.; Maestro I.; Nozal V.; Barrado-Gil L.; Cuesta-Geijo M.&#xC1;.; Urquiza J.; Ram&#xED;rez D.; Alonso C.; Campillo N.E.; Martinez A.; COVID-19: Drug targets and potential treatments. J Med Chem 2020,63(21),12359-12386","journal-title":"J Med Chem"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1016\/S2665-9913(20)30309-X","volume":"2","author":"Robinson P.C.","year":"2020","unstructured":"Robinson P.C.; Richards D.; Tanner H.L.; Feldmann M.; Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol 2020,2(11),e653-e655","journal-title":"Lancet Rheumatol"},{"author":"Malone RW","key":"ref=87","unstructured":"Malone RW; Tisdall P;"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"107969","DOI":"10.1016\/j.intimp.2021.107969","volume":"99","author":"Alavi Darazam I.","year":"2021","unstructured":"Alavi Darazam I.; Shokouhi S.; Mardani M.; Pourhoseingholi M.A.; Rabiei M.M.; Hatami F.; Shabani M.; Moradi O.; Gharehbagh F.J.; Irvani S.S.N.; Amirdosara M.; Hajiesmaeili M.; Rezaei O.; Khoshkar A.; Lotfollahi L.; Gachkar L.; Dehbsneh H.S.; Khalili N.; Soleymaninia A.; Kusha A.H.; Shoushtari M.T.; Torabinavid P.; Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. Int Immunopharmacol 2021,99,107969","journal-title":"Int Immunopharmacol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"Caly L.","year":"2020","unstructured":"Caly L.; Druce J.D.; Catton M.G.; Jans D.A.; Wagstaff K.M.; The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020,178,104787","journal-title":"Antiviral Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1002\/jmv.26078","volume":"92","author":"Chakraborty C.","year":"2020","unstructured":"Chakraborty C.; Sharma A.R.; Bhattacharya M.; Sharma G.; Lee S.S.; Agoramoorthy G.; COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. J Med Virol 2020,92(11),2260-2262","journal-title":"J Med Virol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"11871402.v1","DOI":"10.26434\/chemrxiv.11871402.v1","author":"Smith M.","year":"2020","unstructured":"Smith M.; Smith J.C.; Repurposing therapeutics for the Wuhan coronavirus nCov-2019: Supercomputer-based docking to the viral S protein and human ACE2 interface. Chemrxiv 2020,11871402.v1","journal-title":"Chemrxiv"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","volume":"81","author":"Cantini F.","year":"2020","unstructured":"Cantini F.; Niccoli L.; Matarrese D.; Nicastri E.; Stobbione P.; Goletti D.; Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect 2020,81(2),318-356","journal-title":"J Infect"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/adt.2020.996","volume":"18","author":"Mucke H.A.M.","year":"2020","unstructured":"Mucke H.A.M.; COVID-19 and the drug repurposing tsunami. Assay Drug Dev Technol 2020,18(5),211-214","journal-title":"Assay Drug Dev Technol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1080\/07391102.2020.1758791","volume":"39","author":"Elmezayen A.D.","year":"2021","unstructured":"Elmezayen A.D.; Al-Obaidi, A.; &#x15E; ahin, A.T.; Yelek&#xE7;i, K. Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. J Biomol Struct Dyn 2021,39(8),2980-2992","journal-title":"J Biomol Struct Dyn"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2020.22760","volume":"324","author":"Lenze E.J.","year":"2020","unstructured":"Lenze E.J.; Mattar C.; Zorumski C.F.; Stevens A.; Schweiger J.; Nicol G.E.; Miller J.P.; Yang L.; Yingling M.; Avidan M.S.; Reiersen A.M.; Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA 2020,324(22),2292-2300","journal-title":"JAMA"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"588654","DOI":"10.3389\/fphar.2020.588654","volume":"11","author":"Sultana J.","year":"2020","unstructured":"Sultana J.; Crisafulli S.; Gabbay F.; Lynn E.; Shakir S.; Trifir&#xF2; G.; Challenges for drug repurposing in the COVID-19 Pandemic Era. Front Pharmacol 2020,11,588654","journal-title":"Front Pharmacol"},{"journal-title":"Emergency use authorization- FDA;2020","key":"ref=97","unstructured":"Emergency use authorization- FDA;2020 Food and Drug AdministrationAvailable from:  Accessed 7 July 2021"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","volume":"2","author":"Cavalli G.","year":"2020","unstructured":"Cavalli G.; De Luca G.; Campochiaro C.; Della-Torre E.; Ripa M.; Canetti D.; Oltolini C.; Castiglioni B.; Tassan Din C.; Boffini N.; Tomelleri A.; Farina N.; Ruggeri A.; Rovere-Querini P.; Di Lucca G.; Martinenghi S.; Scotti R.; Tresoldi M.; Ciceri F.; Landoni G.; Zangrillo A.; Scarpellini P.; Dagna L.; Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol 2020,2(6),e325-e331","journal-title":"Lancet Rheumatol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejim.2020.05.021","volume":"76","author":"Campochiaro C.","year":"2020","unstructured":"Campochiaro C.; Della-Torre E.; Cavalli G.; De Luca G.; Ripa M.; Boffini N.; Tomelleri A.; Baldissera E.; Rovere-Querini P.; Ruggeri A.; Monti G.; De Cobelli F.; Zangrillo A.; Tresoldi M.; Castagna A.; Dagna L.; Efficacy and safety of tocilizumab in severe COVID-19 patients: A single-centre retrospective cohort study. Eur J Intern Med 2020,76,43-49","journal-title":"Eur J Intern Med"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12249-020-01744-7","volume":"21","author":"Wang J.","year":"2020","unstructured":"Wang J.; Peng Y.; Xu H.; Cui Z.; Williams R.O.; The COVID-19 vaccine Race: Challenges and opportunities in vaccine formulation. AAPS PharmSciTech 2020,21(6),225","journal-title":"AAPS PharmSciTech"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"Bao L.","year":"2020","unstructured":"Bao L.; Deng W.; Huang B.; Gao H.; Liu J.; Ren L.; Wei Q.; Yu P.; Xu Y.; Qi F.; Qu Y.; Li F.; Lv Q.; Wang W.; Xue J.; Gong S.; Liu M.; Wang G.; Wang S.; Song Z.; Zhao L.; Liu P.; Zhao L.; Ye F.; Wang H.; Zhou W.; Zhu N.; Zhen W.; Yu H.; Zhang X.; Guo L.; Chen L.; Wang C.; Wang Y.; Wang X.; Xiao Y.; Sun Q.; Liu H.; Zhu F.; Ma C.; Yan L.; Yang M.; Han J.; Xu W.; Tan W.; Peng X.; Jin Q.; Wu G.; Qin C.; The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020,583(7818),830-833","journal-title":"Nature"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"Lee W.S.","year":"2020","unstructured":"Lee W.S.; Wheatley A.K.; Kent S.J.; DeKosky B.J.; Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol 2020,5(10),1185-1191","journal-title":"Nat Microbiol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41392-020-00352-y","volume":"5","author":"Dong Y.","year":"2020","unstructured":"Dong Y.; Dai T.; Wei Y.; Zhang L.; Zheng M.; Zhou F.; A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther 2020,5(1),237","journal-title":"Signal Transduct Target Ther"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"Eastman R.T.","year":"2020","unstructured":"Eastman R.T.; Roth J.S.; Brimacombe K.R.; Simeonov A.; Shen M.; Patnaik S.; Hall M.D.; Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 2020,6(5),672-683","journal-title":"ACS Cent Sci"},{"key":"ref=105","unstructured":"COVID-19 Weekly Epidemiological Update by World Health Organization.. 2021. Available from:(Accessed on 4 Apr 2022)."},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/01652176.2020.1727993","volume":"40","author":"Malik Y.S.","year":"2020","unstructured":"Malik Y.S.; Sircar S.; Bhat S.; Sharun K.; Dhama K.; Dadar M.; Tiwari R.; Chaicumpa W.; Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q 2020,40(1),68-76","journal-title":"Vet Q"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jmii.2020.02.001","volume":"53","author":"Lee P.I.","year":"2020","unstructured":"Lee P.I.; Hsueh P.R.; Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect 2020,53(3),365-367","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"101873","DOI":"10.1016\/j.tmaid.2020.101873","volume":"37","author":"Gendrot M.","year":"2020","unstructured":"Gendrot M.; Andreani J.; Boxberger M.; Jardot P.; Fonta I.; Le Bideau M.; Duflot I.; Mosnier J.; Rolland C.; Bogreau H.; Hutter S.; La Scola B.; Pradines B.; Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. Travel Med Infect Dis 2020,37,101873","journal-title":"Travel Med Infect Dis"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"101578","DOI":"10.1016\/j.tmaid.2020.101578","volume":"33","author":"Rodr&#xED;guez-Morales A.J.","year":"2020","unstructured":"Rodr&#xED;guez-Morales A.J.; MacGregor K.; Kanagarajah S.; Patel D.; Schlagenhauf P.; Going global - Travel and the 2019 novel coronavirus. Travel Med Infect Dis 2020,33,101578","journal-title":"Travel Med Infect Dis"},{"key":"ref=110","first-page":"CD015017","volume":"7","author":"Popp M.","year":"2021","unstructured":"Popp M.; Stegemann M.; Metzendorf M-I.; Gould S.; Kranke P.; Meybohm P.; Skoetz N.; Weibel S.; Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2021,7(7),CD015017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.aimed.2020.07.009","volume":"7","author":"Arentz S.","year":"2020","unstructured":"Arentz S.; Hunter J.; Yang G.; Goldenberg J.; Beardsley J.; Myers S.P.; Mertz D.; Leeder S.; Zinc for the prevention and treatment of SARS-CoV-2 and other acute viral respiratory infections: a rapid review. Adv Integr Med 2020,7(4),252-260","journal-title":"Adv Integr Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1016\/j.bmcl.2013.08.112","volume":"23","author":"Turlington M.","year":"2013","unstructured":"Turlington M.; Chun A.; Tomar S.; Eggler A.; Grum-Tokars V.; Jacobs J.; Daniels J.S.; Dawson E.; Saldanha A.; Chase P.; Baez-Santos Y.M.; Lindsley C.W.; Hodder P.; Mesecar A.D.; Stauffer S.R.; Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. Bioorg Med Chem Lett 2013,23(22),6172-6177","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"561334","DOI":"10.3389\/fphar.2020.561334","volume":"11","author":"Verma S.","year":"2020","unstructured":"Verma S.; Twilley D.; Esmear T.; Oosthuizen C.B.; Reid A.M.; Nel M.; Lall N.; Anti-SARS-CoV natural products with the potential to inhibit SARS-CoV-2 (COVID-19). Front Pharmacol 2020,11,561334","journal-title":"Front Pharmacol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1080\/09553002.2020.1818865","volume":"96","author":"Verma A.","year":"2020","unstructured":"Verma A.; Adhikary A.; Woloschak G.; Dwarakanath B.S.; Papineni R.V.L.; A combinatorial approach of a polypharmacological adjuvant 2-deoxy-D-glucose with low dose radiation therapy to quell the cytokine storm in COVID-19 management. Int J Radiat Biol 2020,96(11),1323-1328","journal-title":"Int J Radiat Biol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"Wu F.","year":"2020","unstructured":"Wu F.; Zhao S.; Yu B.; Chen Y.M.; Wang W.; Song Z.G.; Hu Y.; Tao Z.W.; Tian J.H.; Pei Y.Y.; Yuan M.L.; Zhang Y.L.; Dai F.H.; Liu Y.; Wang Q.M.; Zheng J.J.; Xu L.; Holmes E.C.; Zhang Y.Z.; A new coronavirus associated with human respiratory disease in China. Nature 2020,579(7798),265-269","journal-title":"Nature"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"Huang C.","year":"2020","unstructured":"Huang C.; Wang Y.; Li X.; Ren L.; Zhao J.; Hu Y.; Zhang L.; Fan G.; Xu J.; Gu X.; Cheng Z.; Yu T.; Xia J.; Wei Y.; Wu W.; Xie X.; Yin W.; Li H.; Liu M.; Xiao Y.; Gao H.; Guo L.; Xie J.; Wang G.; Jiang R.; Gao Z.; Jin Q.; Wang J.; Cao B.; Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020,395(10223),497-506","journal-title":"Lancet"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/0973-7847.134229","volume":"8","author":"Parasuraman S.","year":"2014","unstructured":"Parasuraman S.; Thing G.S.; Dhanaraj S.A.; Polyherbal formulation: Concept of ayurveda. Pharmacogn Rev 2014,8(16),73-80","journal-title":"Pharmacogn Rev"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.3390\/molecules25215017","volume":"25","author":"Al-Hatamleh M.A.I.","year":"2020","unstructured":"Al-Hatamleh M.A.I.; Hatmal M.M.; Sattar K.; Ahmad S.; Mustafa M.Z.; Bittencourt M.C.; Mohamud R.; Antiviral and immunomodulatory effects of phytochemicals from honey against COVID-19: Potential mechanisms of action and future directions. Molecules 2020,25(21),5017","journal-title":"Molecules"},{"key":"ref=119","author":"Hardin J.W.","year":"1974","unstructured":"Hardin J.W.; Arena J.M.;  Human Poisoning from Native and Cultivated Plants 1974","journal-title":"Human Poisoning from Native and Cultivated Plants"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/jmv.1890150110","volume":"15","author":"Kaul T.N.","year":"1985","unstructured":"Kaul T.N.; Middleton E.; Ogra P.L.; Antiviral effect of flavonoids on human viruses. J Med Virol 1985,15(1),71-79","journal-title":"J Med Virol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jep.2013.04.040","volume":"148","author":"Feng Yeh C.","year":"2013","unstructured":"Feng Yeh C.; Wang K.C.; Chiang L.C.; Shieh D.E.; Yen M.H.; San Chang J.; Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. J Ethnopharmacol 2013,148(2),466-473","journal-title":"J Ethnopharmacol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"Hu B.","year":"2021","unstructured":"Hu B.; Guo H.; Zhou P.; Shi Z.L.; Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021,19(3),141-154","journal-title":"Nat Rev Microbiol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.7164\/antibiotics.35.1454","volume":"35","author":"Gerth K.","year":"1982","unstructured":"Gerth K.; Irschik H.; Reichenbach H.; Trowitzsch W.; The myxovirescins, a family of antibiotics from Myxococcus virescens (Myxobacterales). J Antibiot 1982,35(11),1454-1459","journal-title":"J Antibiot"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1111\/febs.15639","volume":"288","author":"Tan K.","year":"2021","unstructured":"Tan K.; Lim Y.; Viruses join the circular RNA world. FEBS J 2021,288(15),4488-4502","journal-title":"FEBS J"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/AAC.15.3.361","volume":"15","author":"Burg R.W.","year":"1979","unstructured":"Burg R.W.; Miller B.M.; Baker E.E.; Birnbaum J.; Currie S.A.; Hartman R.; Kong Y.L.; Monaghan R.L.; Olson G.; Putter I.; Tunac J.B.; Wallick H.; Stapley E.O.; Oiwa R.; Omura S.; Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother 1979,15(3),361-367","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0272-0590(92)90165-E","volume":"19","author":"Chang J.C.F.","year":"1992","unstructured":"Chang J.C.F.; Walberg J.A.; Campbell W.R.; One-year dietary toxicity study with methidathion in beagle dogs. Fundam Appl Toxicol 1992,19(2),307-314","journal-title":"Fundam Appl Toxicol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"152956","DOI":"10.1016\/j.phymed.2019.152956","volume":"62","author":"Bailly C.","year":"2019","unstructured":"Bailly C.; Cepharanthine: An update of its mode of action, pharmacological properties and medical applications. Phytomedicine 2019,62,152956","journal-title":"Phytomedicine"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-020-00243-2","volume":"5","author":"Yang L.","year":"2020","unstructured":"Yang L.; Liu S.; Liu J.; Zhang Z.; Wan X.; Huang B.; Chen Y.; Zhang Y.; COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther 2020,5(1),128","journal-title":"Signal Transduct Target Ther"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/biom9110696","volume":"9","author":"Kim D.E.","year":"2019","unstructured":"Kim D.E.; Min J.S.; Jang M.S.; Lee J.Y.; Shin Y.S.; Song J.H.; Kim H.R.; Kim S.; Jin Y.H.; Kwon S.; Natural Bis-Benzylisoquinoline Alkaloids-Tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells. Biomolecules 2019,9(11),696","journal-title":"Biomolecules"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0040-4020(01)98621-1","volume":"20","author":"Blossey E.C.","year":"1964","unstructured":"Blossey E.C.; Budzikiewicz H.; Ohashi M.; Fodor G.; Djerassi C.; Mass spectrometry in structural and stereochemical problems\u2014XXXIX: Tropane alkaloids. Tetrahedron 1964,20(3),585-595","journal-title":"Tetrahedron"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/ph10040081","volume":"10","author":"Muchtaridi M.","year":"2017","unstructured":"Muchtaridi M.; Syahidah H.N.; Subarnas A.; Yusuf M.; Bryant S.D.; Langer T.; Molecular docking and 3D-pharmacophore modeling to study the interactions of chalcone derivatives with estroge receptor alpha. Pharmaceuticals (Basel), 2017,10(4),81","journal-title":"Pharmaceuticals (Basel),"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.22271\/phyto.2020.v9.i3t.11460","volume":"9","author":"Brahmbhatt R.V.","year":"2020","unstructured":"Brahmbhatt R.V.; Herbal medicines in management and prevention of COVID-19. J Pharmacogn Phytochem 2020,9(3),1221-1223","journal-title":"J Pharmacogn Phytochem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.talanta.2008.10.022","volume":"77","author":"Yue H.","year":"2009","unstructured":"Yue H.; Pi Z.; Song F.; Liu Z.; Cai Z.; Liu S.; Studies on the aconitine-type alkaloids in the roots of Aconitum carmichaelii Debx. by HPLC\/ESIMS\/MS(n). Talanta 2009,77(5),1800-1807","journal-title":"Talanta"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"16","DOI":"10.26452\/ijrps.v11iSPL1.1976","volume":"1","author":"Goothy S.S.","year":"2020","unstructured":"Goothy S.S.; Goothy S.; Ayurveda\u2019s holistic lifestyle approach for the management of Coronavirus disease (COVID-19): Possible role of tulsi. Int J Res Pharm Sci 2020,1(11),16-18","journal-title":"Int J Res Pharm Sci"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaim.2020.06.012","volume":"11","author":"Tillu G.","year":"2020","unstructured":"Tillu G.; Salvi S.; Patwardhan B.; AYUSH for COVID-19 management. J Ayurveda Integr Med 2020,11(2),95-96","journal-title":"J Ayurveda Integr Med"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3390\/molecules26061767","volume":"26","author":"Abouelela M.E.","year":"2021","unstructured":"Abouelela M.E.; Assaf H.K.; Abdelhamid R.A.; Elkhyat E.S.; Sayed A.M.; Oszako T.; Belbahri L.; El Zowalaty A.E.; Abdelkader M.S.A.; Identification of potential SARS-CoV-2 main protease and spike protein inhibitors from the genus aloe: An in-silico study for drug development. Molecules 2021,26(6),1767","journal-title":"Molecules"},{"key":"ref=137","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaim.2020.07.002","author":"Gandhi A.J.","year":"2020","unstructured":"Gandhi A.J.; Rupareliya J.D.; Shukla V.J.; Donga S.B.; Acharya R.; An ayurvedic perspective along with in silico study of the drugs for the management of SARS-CoV-2. J Ayur. Integr Med 2020","journal-title":"Integr Med"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3389\/fimmu.2020.01441","volume":"11","author":"Garc&#xED;a L.F.","year":"2020","unstructured":"Garc&#xED;a L.F.; Immune Response, inflammation, and the clinical spectrum of COVID-19. Front Immunol 2020,11,1441","journal-title":"Front Immunol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.3389\/fimmu.2020.02037","volume":"11","author":"Mortaz E.","year":"2020","unstructured":"Mortaz E.; Tabarsi P.; Varahram M.; Folkerts G.; Adcock I.M.; The immune response and immunopathology of COVID-19. Front Immunol 2020,11,2037","journal-title":"Front Immunol"},{"key":"ref=140","author":"Liu X.","year":"2020","unstructured":"Liu X.; Zhang B.; Jin Z.; Yang H.; Rao Z.;  The crystal structure of COVID-19 main protease in complex with an inhibitor N3 2020","journal-title":"The crystal structure of COVID-19 main protease in complex with an inhibitor N3"},{"year":"2021","author":"Asarnow D.","key":"ref=141","unstructured":"Asarnow D.; Charles C.; Cheng Y;  SARS-CoV-2 spike glycoprotein:Fab 3D11 complex. 2021"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"Berman H.M.","year":"2000","unstructured":"Berman H.M.; Westbrook J.; Feng Z.; Gilliland G.; Bhat T.N.; Weissig H.; Shindyalov I.N.; Bourne P.E.; The protein data bank. Nucleic Acids Res 2000,28(1),235-242","journal-title":"Nucleic Acids Res"},{"author":"Andi B.","key":"ref=143","unstructured":"Andi B.; Kumaran D.; Kreitler D.F.; Crystal structure of SARS-CoV-2 main protease (3CLpro\/Mpro) in the apo form at 1.2 A resolution and a possible capture of zinc binding intermediate 2020.Available from: 10.2210\/pdb7K3T\/pdb (Accessed on 4 Apr 2022)"},{"key":"ref=144","author":"Bulut H.","year":"2020","unstructured":"Bulut H.; Hattori S.I.; Das D.; Murayama K.; Mitsuya H.;  Crystal structure of SARS-CoV-2 main protease in complex with an inhibitor GRL-2420 2020","journal-title":"Crystal structure of SARS-CoV-2 main protease in complex with an inhibitor GRL-2420"},{"year":"2021","author":"Gajiwala K.S.","key":"ref=145","unstructured":"Gajiwala K.S.; Ferre R.A.; Liu W.; Ryan K.; Structure of SARS CoV-2 main protease shows simultaneous processing of its N- and C-terminii. 2021"},{"year":"2020","author":"Wang Y.C.","key":"ref=146","unstructured":"Wang Y.C.; Yang C.S.; Hou M.H.; Tsai C.L.; Chou Y.Z.; Chen Y; SARS-CoV-2 main protease (Mpro) apo structure (space group, 212121). 2020"},{"year":"2020","author":"Sacco M.","key":"ref=147","unstructured":"Sacco M.; Wang J.; Chen Y;  Crystal structure of the SARS-CoV-2 (COVID-19) main protease in complex with noncovalent inhibitor Jun8-76-3A 2020"},{"year":"2021","author":"Sauer M.M.","key":"ref=148","unstructured":"Sauer M.M.; Park Y.J.; Veesler D;  B6 Fab fragment bound to the SARS-CoV\/-2 spike stem helix peptide. 2021"},{"year":"2020","author":"Cong Y.","key":"ref=149","unstructured":"Cong Y.; Wang Y.F.;  S-2H2-F1 structure, one RBD is up and two RBDs are down, only up RBD binds with a 2H2 Fab 2020"},{"key":"ref=150","author":"Yan R.H.","year":"2021","unstructured":"Yan R.H.; Zhang Y.Y.;  Conformation 1 of S-ACE2-B0AT1 ternary complex 2021","journal-title":"Conformation 1 of S-ACE2-B0AT1 ternary complex"},{"year":"2020","author":"Bangaru S.","key":"ref=151","unstructured":"Bangaru S.; Turner H.L.; Ozorowski G.; Antanasijevic A.; Ward A.; A.B Structure of SARS-CoV-2 3Q-2P full-length dimers of spike trimers 2020"},{"key":"ref=152","author":"Srinivasan V.","year":"2021","unstructured":"Srinivasan V.; Gunther S.;  Structure of SARS-CoV-2 Papain-like protease PLpro 2021","journal-title":"Structure of SARS-CoV-2 Papain-like protease PLpro"},{"key":"ref=153","author":"Osipiuk J.","year":"2020","unstructured":"Osipiuk J.; Jedrzejczak R.;  The crystal structure of papain-like protease of SARS CoV-2 2020","journal-title":"The crystal structure of papain-like protease of SARS CoV-2"},{"key":"ref=154","author":"Fu Z.","year":"2020","unstructured":"Fu Z.; Huang H;  SARS CoV-2 PLpro in complex with GRL0617 2020","journal-title":"SARS CoV-2 PLpro in complex with GRL0617"},{"year":"2020","author":"Correy G.J.","key":"ref=155","unstructured":"Correy G.J.; Young I.D.; Thompson M.C.; Fraser J.S;  Crystal structure of SARS-CoV-2 NSP3 macrodomain (C2 crystal form,100 K).  2020"},{"key":"ref=156","author":"Correy G.J.","year":"2020","unstructured":"Correy G.J.; Young I.D.; Thompson M.C.; Fraser J.;  S Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000084843283 2020","journal-title":"S Crystal structure of SARS-CoV-2 NSP3 macrodomain in complex with ZINC000084843283"},{"year":"2020","author":"Wilamowski M.","key":"ref=157","unstructured":"Wilamowski M.; Kim Y.;  The 1.5 A Crystal structure of the Cofactor complex of NSP7 and the C-terminal Domain of NSP8 from SARS CoV-2. 2020"},{"year":"2020","author":"Fisher S.Z.","key":"ref=158","unstructured":"Fisher S.Z.; ; Kozielski, F Nonstructural protein 10 (nsp10) from SARS CoV-2. 2020"},{"key":"ref=159","author":"Hall P.D.","year":"2020","unstructured":"Hall P.D.; Nelson C.A.; Fremont D.;  H Structure of the SARS-CoV-2 ORF8 encoded accessory protein 2020","journal-title":"H Structure of the SARS-CoV-2 ORF8 encoded accessory protein"},{"year":"2020","author":"Minasov G.","key":"ref=160","unstructured":"Minasov G.; Shuvalova L.; Rosas-Lemus M.; Kiryukhina O.; Brunzelle J.S.; Satchell K.J.F;  Crystal structure of SARS-CoV-2 Nsp16\/10 Heterodimer in complex with (m7GpppA2m)pUpUpApApA (Cap-1), S-Adenosyl-Lhomocysteine (SAH) and two Magnesium (Mg) ions. 2020"},{"year":"2020","author":"Kim Y.","key":"ref=161","unstructured":"Kim Y.; Maltseva N.;  2020"},{"year":"2020","author":"Littler D.R.","key":"ref=162","unstructured":"Littler D.R.; Gully B.S.; Riboldi-Tunnicliffe A.; Rossjohn J; SARS-CoV-2 Nsp9 RNA-replicase. 2020"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1080\/07391102.2020.1752802","volume":"39","author":"Muralidharan N.","year":"2021","unstructured":"Muralidharan N.; Sakthivel R.; Velmurugan D.; Gromiha M.M.; Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J Biomol Struct Dyn 2021,39(7),2673-2678","journal-title":"J Biomol Struct Dyn"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","volume":"60","author":"Wang J.","year":"2020","unstructured":"Wang J.; Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model 2020,60(6),3277-3286","journal-title":"J Chem Inf Model"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"569665","DOI":"10.3389\/fphar.2020.569665","volume":"11","author":"Vaidya N.A.","year":"2020","unstructured":"Vaidya N.A.; Vyas R.; Computational studies of Hydroxychloroquine and chloroquine metabolites as possible candidates for coronavirus (COVID-19) treatment. Front Pharmacol 2020,11,569665","journal-title":"Front Pharmacol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"9047","DOI":"10.1038\/s41598-021-88153-3","volume":"11","author":"Mongia A.","year":"2021","unstructured":"Mongia A.; Saha S.K.; Chouzenoux E.; Majumdar A.; A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials. Sci Rep 2021,11(1),9047","journal-title":"Sci Rep"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2019.1661876","volume":"39","author":"Ahmad S.","year":"2021","unstructured":"Ahmad S.; Abbasi H.W.; Shahid S.; Gul S.; Abbasi S.W.; Molecular docking, simulation and MM-PBSA studies of Nigella sativa compounds: A computational quest to identify potential natural antiviral for COVID-19 treatment. J Biomol Struct Dyn 2021,39(12),1-9","journal-title":"J Biomol Struct Dyn"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s43440-020-00195-y","volume":"73","author":"Kaur H.","year":"2021","unstructured":"Kaur H.; Shekhar N.; Sharma S.; Sarma P.; Prakash A.; Medhi B.; Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. Pharmacol Rep 2021,73(3),736-749","journal-title":"Pharmacol Rep"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1021\/acs.jpclett.0c02278","volume":"11","author":"Batra R.","year":"2020","unstructured":"Batra R.; Chan H.; Kamath G.; Ramprasad R.; Cherukara M.J.; Sankaranarayanan S.K.R.S.; Screening of therapeutic agents for COVID-19 using machine learning and ensemble docking studies. J Phys Chem Lett 2020,11(17),7058-7065","journal-title":"J Phys Chem Lett"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"106012","DOI":"10.1016\/j.ijantimicag.2020.106012","volume":"56","author":"Yu R.","year":"2020","unstructured":"Yu R.; Chen L.; Lan R.; Shen R.; Li P.; Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Int J Antimicrob Agents 2020,56(2),106012","journal-title":"Int J Antimicrob Agents"},{"key":"ref=171","first-page":"1","author":"Anwar F.","year":"2020","unstructured":"Anwar F.; Altayb H.N.; Al-Abbasi F.A.; Al-Malki A.L.; Kamal M.A.; Kumar V.; Antiviral effects of probiotic metabolites on COVID-19. J Biomol Struct Dyn 2020,1-10","journal-title":"J Biomol Struct Dyn"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"110168","DOI":"10.1016\/j.chaos.2020.110168","volume":"140","author":"Benlloch J.M.","year":"2020","unstructured":"Benlloch J.M.; Cort&#xE9;s J.C.; Mart&#xED;nez-Rodr&#xED;guez D.; Juli&#xE1;n R.S.; Villanueva R.J.; Effect of the early use of antivirals on the COVID-19 pandemic. A computational network modeling approach. Chaos Solitons Fractals 2020,140,110168","journal-title":"Chaos Solitons Fractals"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1515\/chem-2021-0024","volume":"19","author":"Abdellatiif M.H.","year":"2021","unstructured":"Abdellatiif M.H.; Ali A.; Ali A.; Hussien M.A.; Computational studies by molecular docking of some antiviral drugs with COVID-19 receptors are an approach to medication for COVID-19. Open Chem J 2021,19(1),245-264","journal-title":"Open Chem J"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"100090","DOI":"10.1016\/j.patter.2020.100090","volume":"1","author":"Kuleshov M.V.","year":"2020","unstructured":"Kuleshov M.V.; Stein D.J.; Clarke D.J.B.; Kropiwnicki E.; Jagodnik K.M.; Bartal A.; Evangelista J.E.; Hom J.; Cheng M.; Bailey A.; Zhou A.; Ferguson L.B.; Lachmann A.; Ma\u2019ayan A.; The COVID-19 drug and gene set library. Patterns 2020,1(6),100090","journal-title":"Patterns"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.phyplu.2020.100002","volume":"1","author":"Parida P.K.","year":"2021","unstructured":"Parida P.K.; Paul D.; Chakravorty D.; Nature\u2019s therapy for COVID-19: Targeting the vital Non-Structural Proteins (NSP) from SARS-CoV-2 with phytochemicals from Indian medicinal plants. Phytomedicine Plus 2021,1(1),100002","journal-title":"Phytomedicine Plus"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jphs.2021.05.004","volume":"147","author":"Johnson T.O.","year":"2021","unstructured":"Johnson T.O.; Adegboyega A.E.; Iwaloye O.; Eseola O.A.; Plass W.; Afolabi B.; Rotimi D.; Ahmed E.I.; Albrakati A.; Batiha G.E.; Adeyemi O.S.; Computational study of the therapeutic potentials of a new series of imidazole derivatives against SARS-CoV-2. J Pharmacol Sci 2021,147(1),62-71","journal-title":"J Pharmacol Sci"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Zhou Y.","year":"2020","unstructured":"Zhou Y.; Hou Y.; Shen J.; Huang Y.; Martin W.; Cheng F.; Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov 2020,6,14","journal-title":"Cell Discov"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/v12040404","volume":"12","author":"Cava C.","year":"2020","unstructured":"Cava C.; Bertoli G.; Castiglioni I.; In silico discovery of candidate drugs against Covid-19. Viruses 2020,12(4),404","journal-title":"Viruses"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"609","DOI":"10.12688\/f1000research.23996.2","volume":"9","author":"He B.","year":"2020","unstructured":"He B.; Garmire L.; Prediction of repurposed drugs for treating lung injury in COVID-19. F1000 Res 2020,9,609","journal-title":"F1000 Res"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"Wu C.","year":"2020","unstructured":"Wu C.; Liu Y.; Yang Y.; Zhang P.; Zhong W.; Wang Y.; Wang Q.; Xu Y.; Li M.; Li X.; Zheng M.; Chen L.; Li H.; Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020,10(5),766-788","journal-title":"Acta Pharm Sin B"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"117652","DOI":"10.1016\/j.lfs.2020.117652","volume":"252","author":"Shah B.","year":"2020","unstructured":"Shah B.; Modi P.; Sagar S.R.; In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sci 2020,252,117652","journal-title":"Life Sci"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"117627","DOI":"10.1016\/j.lfs.2020.117627","volume":"251","author":"Kandeel M.","year":"2020","unstructured":"Kandeel M.; Al-Nazawi M.; Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci 2020,251,117627","journal-title":"Life Sci"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1080\/07391102.2020.1768902","volume":"39","author":"Mahanta S.","year":"2021","unstructured":"Mahanta S.; Chowdhury P.; Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: An in silico-based approach. J Biomol Struct Dyn 2021,39(10),3802-3811","journal-title":"J Biomol Struct Dyn"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"236","DOI":"10.6026\/97320630016236","volume":"16","author":"Odhar H.A.","year":"2020","unstructured":"Odhar H.A.; Ahjel S.W.; Albeer A.A.M.A.; Hashim A.F.; Rayshan A.M.; Humadi S.S.; Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus. Bioinformation 2020,16(3),236-244","journal-title":"Bioinformation"},{"key":"ref=185","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1080\/07391102.2020.1768151","volume":"39","author":"Mittal L.","year":"2021","unstructured":"Mittal L.; Kumari A.; Srivastava M.; Singh M.; Asthana S.; Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach. J Biomol Struct Dyn 2021,39(10),3662-3680","journal-title":"J Biomol Struct Dyn"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1080\/07391102.2020.1763201","volume":"39","author":"Das S.","year":"2021","unstructured":"Das S.; Sarmah S.; Lyndem S.; Singha Roy A.; An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. J Biomol Struct Dyn 2021,39(9),3347-3357","journal-title":"J Biomol Struct Dyn"},{"key":"ref=187","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv.12003930.v1","author":"Farag A.","year":"2020","unstructured":"Farag A.; Wang P.; Ahmed M.; Sadek H.; Identification of FDA approved drugs targeting COVID-19 virus by structure-based drug repositioning. ChemRxiv 2020","journal-title":"ChemRxiv"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.3390\/ijms21113793","volume":"21","author":"Gimeno A.","year":"2020","unstructured":"Gimeno A.; Mestres-Truyol J.; Ojeda-Montes M.J.; Macip G.; Saldivar-Espinoza B.; Cereto-Massagu&#xE9; A.; Pujadas G.; Garcia-Vallv&#xE9; S.; Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition. Int J Mol Sci 2020,21(11),3793","journal-title":"Int J Mol Sci"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"Elfiky A.A.","year":"2020","unstructured":"Elfiky A.A.; Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020,253,117592","journal-title":"Life Sci"},{"key":"ref=190","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1080\/07391102.2020.1751300","volume":"39","author":"Gupta M.K.","year":"2021","unstructured":"Gupta M.K.; Vemula S.; Donde R.; Gouda G.; Behera L.; Vadde R.; In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. J Biomol Struct Dyn 2021,39(7),2617-2627","journal-title":"J Biomol Struct Dyn"},{"key":"ref=191","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1080\/07391102.2020.1758791","volume":"39","author":"Elmezayen A.D.","year":"2021","unstructured":"Elmezayen A.D.; Al-Obaidi, A.; &#x15E; ahin, A.T.; Yelek&#xE7;i, K. Drug repurposing for coronavirus (COVID-19): In silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. J Biomol Struct Dyn 2021,39(8),2980-2992","journal-title":"J Biomol Struct Dyn"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"101646","DOI":"10.1016\/j.tmaid.2020.101646","volume":"35","author":"Hall D.C.","year":"2020","unstructured":"Hall D.C.; Ji H.F.; A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis 2020,35,101646","journal-title":"Travel Med Infect Dis"},{"key":"ref=193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2019.1661876","volume":"39","author":"de Oliveira O.V.","year":"2021","unstructured":"de Oliveira O.V.; Rocha G.B.; Paluch A.S.; Costa L.T.; Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening. J Biomol Struct Dyn 2021,39(11),1-10","journal-title":"J Biomol Struct Dyn"},{"key":"ref=194","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.22.951178","author":"Park T.","year":"2020","unstructured":"Park T.; Lee S.Y.; Kim S.; Kim M.J.; Kim H.G.; Jun S.; Park D.; Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2. BioRxiv \n\n2020","journal-title":"BioRxiv"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"572718","DOI":"10.3389\/fphys.2020.572718","volume":"11","author":"Wang M.","year":"2020","unstructured":"Wang M.; Baker J.S.; Quan W.; Shen S.; Fekete G.; Gu Y.; A preventive role of exercise across the coronavirus 2 (SARS-CoV-2) pandemic. Front Physiol 2020,11,572718","journal-title":"Front Physiol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/1875399X02013010120","volume":"13","author":"Hammami N.","year":"2020","unstructured":"Hammami N.; Jdidi H.; Frih B.; COVID-19 Pandemic: Physical activity as prevention mean. Open Sports Sci J 2020,13(1),120-122","journal-title":"Open Sports Sci J"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201023666220507003726","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204366\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201023666220507003726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T16:31:38Z","timestamp":1691425898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204366\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":196,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201023666220507003726","relation":{},"ISSN":["1389-2010"],"issn-type":[{"type":"print","value":"1389-2010"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}